@article{9f0160341b2c4712942ce7249a4c24dd,
title = "Managing Nonmetastatic Castration-resistant Prostate Cancer",
abstract = "Nonmetastatic castration-resistant prostate cancer is a heterogeneous clinical state defined by rising prostate-specific antigen on androgen deprivation therapy but without imaging evidence of metastatic disease. New systemic therapies prolong time to metastatic disease. More sensitive imaging modalities will likely redefine this state in the near future.",
keywords = "Apalutamide, Castration-resistant prostate cancer, Enzalutamide, Imaging biomarkers, Metastasis-free survival, Nonmetastatic castration-resistant prostate cancer, Prostate-specific antigen doubling time",
author = "Joaquin Mateo and Karim Fizazi and Silke Gillessen and Axel Heidenreich and Raquel Perez-Lopez and Oyen, {Wim J.G.} and Neal Shore and Matthew Smith and Christopher Sweeney and Bertrand Tombal and Tomlins, {Scott A.} and {de Bono}, {Johann S.}",
note = "Publisher Copyright: {\textcopyright} 2018 The Authors",
year = "2019",
month = feb,
day = "1",
doi = "10.1016/j.eururo.2018.07.035",
language = "English",
volume = "75",
pages = "285--293",
journal = "European Urology",
issn = "0302-2838",
number = "2",
}